Inactive Instrument

Novartis AG Share Price Xetra

Equities

NOT

CH0012005267

Pharmaceuticals

Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 4.9TCr 4.54TCr 4,08600Cr Sales 2025 * 5.08TCr 4.71TCr 4,23900Cr Capitalization 21TCr 19TCr 17,47800Cr
Net income 2024 * 1.05TCr 973.33Cr 88TCr Net income 2025 * 1.21TCr 1.12TCr 1,00700Cr EV / Sales 2024 * 4.54 x
Net Debt 2024 * 1.29TCr 1.19TCr 1,07500Cr Net Debt 2025 * 1.13TCr 1.05TCr 94TCr EV / Sales 2025 * 4.35 x
P/E ratio 2024 *
19.9 x
P/E ratio 2025 *
17.1 x
Employees 76,057
Yield 2024 *
3.55%
Yield 2025 *
3.68%
Free-Float 85.22%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 48 01/05/01
Director of Finance/CFO 59 01/03/01
Chief Tech/Sci/R&D Officer 62 16/22/16
Members of the board TitleAgeSince
Director/Board Member 62 01/13/01
Director/Board Member 65 28/20/28
Chairman 68 01/13/01
More insiders
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW